AKT1 and breast carcinoma: Compatible with our findings on cell viability, immunoblotting analyses substantiate the suggested disruption of antiapoptotic and proliferative signaling through Akt and Erk in breast cancer cells upon treatment with ZOL/CEL and ZOL/OLA (Figure 5B).